129 related articles for article (PubMed ID: 29557197)
1. Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversies.
Ng K; Duncan S; Shamash J; Alifrangis C
Expert Rev Anticancer Ther; 2018 May; 18(5):431-436. PubMed ID: 29557197
[TBL] [Abstract][Full Text] [Related]
2. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
4. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
5. [Current status and future perspectives in chemotherapy for testicular cancer].
Kawai K
Gan To Kagaku Ryoho; 2003 Feb; 30(2):171-80. PubMed ID: 12610862
[TBL] [Abstract][Full Text] [Related]
6. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
13. The management of poor-prognosis, non-seminomatous germ-cell tumours.
Sirohi B; Huddart R
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):543-52. PubMed ID: 16238142
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C; Bokemeyer C
Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
17. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
Brada M; Horwich A; Peckham MJ
Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
[TBL] [Abstract][Full Text] [Related]
18. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Lorch A; Beyer J
World J Urol; 2017 Aug; 35(8):1177-1184. PubMed ID: 27678272
[TBL] [Abstract][Full Text] [Related]
20. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
